Loading...
•
Mar 31, 2024
TransMedics Q1 2024 Earnings Report
Reported financial results for the quarter ended March 31, 2024.
Key Takeaways
TransMedics reported a strong first quarter with a 133% increase in revenue compared to the previous year, reaching $96.9 million. The company also generated a net income of $12.2 million, or $0.35 per fully diluted share. They are raising their full year 2024 revenue guidance to be in the range of $390 million to $400 million.
Net revenue of $96.9 million, a 133% increase compared to Q1 2023.
Generated net income of $12.2 million or $0.35 per fully diluted share.
OCS Heart and OCS Lung and associated new clinical programs were highlighted at ISHLT annual meeting.
Raising full year 2024 revenue guidance to $390 million to $400 million.
Revenue by Segment
Forward Guidance
TransMedics is raising its full year 2024 revenue guidance to be in the range of $390 million to $400 million, which represents 61% to 66% growth compared to the company’s prior year revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...